Covaxin Trail Results| Bharat Biotech releases Phase III trial results of COVAXIN, also effective against delta infection Bharat Biotech concludes final analysis for Covaxin efficacy says Covaxin is 65.2% eff
COVAXIN Phase III Trial Results Out, Effective Result
- Bharat Biotech released the results of Phase III trial
- Covaccine also found effective against delta variant
- Kovid vaccine has been 93% effective against severe Kovid patients
New Delhi: An important news has come out in the midst of the ongoing fight against Corona. Bharat Biotech has reported the third phase trial results of its COVID vaccine COVAXIN. The efficacy of Covaxin has been 77.8% effective. A US drug developer on Friday said the COVID-19 vaccine developed by Ocugen’s Indian partner Bharat Biotech has been found to be 93.4% effective against severe cases of COVID-19.
Also effective against Delta variants
Covaxin was found to be 77.8% effective in mild, moderate and severe COVID-19 disease, with the vaccine efficacy 93.4% for severe COVID-19 patients. In a phase 3 trial conducted by Bharat Biotech, Covaccine has been found to be 65.2% effective even against the dangerous delta variants. A total of 24,419 people were included during this phase of trial, out of which 12,221 people were given both doses of the original vaccine.
According to what Bharat Biotech claimed in its pre-print analysis, the efficacy of the vaccine is as follows-
- Asymptomatic – 63% Effective
- Mild, moderate and severe cases: 78% effective
- Delta variant: 65% effective
- Severe COVID-19 cases: 93% effective
During the trial, people taking both doses were monitored for two weeks. After this, it was found in the analysis that about 17000 people were given both the doses, out of which 130 got Kovid infection. In this, there were only 24 people who got corona virus after applying both the doses. During the trial, it came out that Covaxin is 67.8% effective on people above 60 years of age and 79.4% effective on people below 60 years of age.
vaccination campaign continues
Let us tell you that a rapid vaccination campaign is going on in India these days. Mainly Bharat Biotech’s Covaccine and Astragenica’s Covishield vaccines are being administered to the people. The Russian vaccine Sputnik has also become available in India, but it is currently available in limited numbers. The Indian government plans to make available 12 crore doses of COVID-19 vaccines covering people above 18 years of age in government and private hospitals across 37 states and union territories (UTS) this month.
#Covaxin #Trail #Results #Bharat #Biotech #releases #Phase #III #trial #results #COVAXIN #effective #delta #infection #Bharat #Biotech #concludes #final #analysis #Covaxin #efficacy #Covaxin #eff